^
MGMT underexpression
Pituitary Gland Carcinoma
temozolomide
Sensitive
:
C3
SDHB mutation
Pituitary Gland Carcinoma
temozolomide
Sensitive
:
C4
MSH2 mutation + MSH6 mutation
Pituitary Gland Carcinoma
pembrolizumab
Sensitive
:
C4
TMB-L + PD-L1 underexpression
Pituitary Gland Carcinoma
nivolumab + ipilimumab
Sensitive
:
C4
STK11 mutation
Pituitary Gland Carcinoma
temozolomide + capecitabine
Resistant
:
C4
STK11 mutation
Pituitary Gland Carcinoma
everolimus
Sensitive
:
C4
ATRX mutation + TP53 mutation + PTEN mutation
Pituitary Gland Carcinoma
temozolomide
Sensitive
:
C4
TMB-H
Pituitary Gland Carcinoma
nivolumab + ipilimumab
Resistant
:
C4
TMB-H
Pituitary Gland Carcinoma
temozolomide
Resistant
:
C4
MSH2 deletion + MSH6 deletion
Pituitary Gland Carcinoma
temozolomide
Resistant
:
C4
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our